771573-87-6

Basic information

• Product Name: 2(1H)-Pyridinone,3-(aminomethyl)-4-methyl-6-phenyl-(9CI)
• Synonyms: 2(1H)-Pyridinone,3-(aminomethyl)-4-methyl-6-phenyl-(9CI)
• CAS NO: 771573-87-6
• Molecular Formula: C13H14N2O
• Molecular Weight: 214.26306
• Product Categories: METHYL
• Mol File: 771573-87-6.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2(1H)-Pyridinone,3-(aminomethyl)-4-methyl-6-phenyl-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 2(1H)-Pyridinone,3-(aminomethyl)-4-methyl-6-phenyl-(9CI)(771573-87-6)
• EPA Substance Registry System: 2(1H)-Pyridinone,3-(aminomethyl)-4-methyl-6-phenyl-(9CI)(771573-87-6)

Safety Data

• Hazardous Substances Data: 771573-87-6(Hazardous Substances Data)

Usage

Structure

Pyridinone derivative with an aminomethyl group and a phenyl group attached to the 4 and 6 positions, respectively

Potential applications

Pharmaceutical industry (development of new drugs), organic synthesis, medicinal chemistry research

Value

Valuable building block for the synthesis of biologically active molecules and pharmaceutical compounds

Possible outcomes

Further research and development could lead to new therapeutic agents with potential medical benefits.

Upstream product

• 4240-97-5 4-methyl-2-phenyl-1,2-dihydro-6-oxo-5-pyridine-carbonitrile 
• 93-91-4 1-phenylbutan-1,3-dione 

Relevant articles and documents

Discovery of quinolone derivatives as antimycobacterial agents

Tuberculosis (TB), an infectious disease caused byMycobacterium tuberculosis(M. tuberculosis), is an important public health issue. Current first-line drugs administered to TB patients have been in use for over 40 years, whereas second-line drugs display strong side effects and poor compliance. Additionally, designing effective regimens to treat patients infected with multi- and extremely-drug-resistant (MDR and XDR) strains of TB is challenging. In this report, we screened our compound library and identified compound1with antituberculosis activity and a minimal inhibitory concentration (MIC) againstM. tuberculosisof 20 μg mL?1. Structure optimization and the structure-activity relationship of1as the lead compound enabled the design and synthesis of a series of quinolone derivatives,6a1-6a2,6b1-6b36,6c1,6d1-6d14,7a1-7a2,7b1-7b2,7c1,8a1-8a5,9a1-9a4and10a1-10a6. These compounds were evaluatedin vitrofor anti-tubercular activity against theM. tuberculosisH37Rv strain. Among them, compounds6b6,6b12and6b21exhibited MIC values in the range of 1.2-3 μg mL?1and showed excellent activity against the tested MDR-TB strain (MIC: 3, 2.9 and 0.9 μg mL?1, respectively). All three compounds were non-toxic toward A549 and Vero cells (>100 and >50 μg mL?1, respectively). In addition, an antibacterial spectrum test carried out using compound6b21showed that this compound specifically inhibitsM. tuberculosis. These can serve as a new starting point for the development of anti-TB agents with therapeutic potential.